GlaxoSmithKline's Tykerb fails in gastric cancer trial; Boehringer, Lilly unveil diabetes-management game;

@FiercePharma: FDA close to resolving all cancer drug shortages; most stem from production halts to fix manufacturing issues. More | Follow @FiercePharma

@EricPFierce: ICYMI: Dr. Reddy's, Fujifilm pull plug on Japanese joint venture. Article | Follow @EricPFierce

@CarlyHFierce: European Commission to crack down on 'pay for delay,' reportedly fine 9 companies including Lundbeck, Merck KGaA, Ranbaxy. Article | Follow @CarlyHFierce

> GlaxoSmithKline's ($GSK) breast cancer drug Tykerb doesn''t boost survival rates in patients with gastric cancer compared with chemo alone, study finds. Report

> Boehringer Ingelheim and Eli Lilly ($LLY) launched an educational digital game to teach desktop and iPad users the importance of managing Type 2 diabetes. Report

> Courts in Ireland and the U.S. temporarily blocked Royalty Pharma's bid for Elan ($ELN). Report

> Adcock Ingram, the South African drugmaker that's up for sale, saw profits decline by 5.4% in the quarter. Report

Medical Device News

@FierceMedDev: Stryker confronts mounting metal hip recall lawsuits. Story | Follow @FierceMedDev

@DamianFierce: St. Jude is targeting FDA approval for its renal denervation device with a new study. Report | Follow @DamianFierce

@MarkHFierce: Get your FMD Fierce 15 nominations in today. | Follow @MarkHFierce

@MichaelGFierce: ICYMI yesterday: Medtronic triggers summer PMA process for drug-eluting balloon. Story | Follow @MichaelGFierce

> Medtronic wins FDA nod, CE mark for angioplasty balloon. Story

> Zimmer boosts bone biz with German buyout. News

> Canon revs up MA med tech R&D operation. Report

>  U of Minnesota fires competitive blast with new med devices center. Item

Biotech News

@FierceBiotech: Trending: Top 10 experimental cancer drugs - 2013. Special report | Follow @FierceBiotech

 @JohnCFierce: Remember the Pluristem scandal last fall? FDA clamps clinical hold on Pluristem PhII stem cell trial. More | Follow @JohnCFierce

@RyanMFierce: J&J backs $biotech startup Protagonist in $14M financing. News | Follow @RyanMFierce

> FDA clamps clinical hold on Pluristem PhII stem cell trial. News

> R&D: Are true drug breakthroughs a thing of the past? More

> AstraZeneca tosses another PhIII failure onto the scrap heap. Report

> Akebia snags $41M financing in anemia-drug race with GlaxoSmithKline, others. Article

> Cardio3 tests Europe's appetite for biotech IPOs. Item

Biotech Research News

@EmilyMFierce: Alterations in one gene may drive allergic, autoimmune diseases. Story | Follow @EmilyMFierce

> $750,000 in grants available to scientific researchers under new program. Report

> NIH lays out effects of sequestration on biomedical research. News

> New agent stops replication of hep C virus in preclinical studies. Article

> Pfizer taps UCSF for small-molecule drug discovery. Story

Pharma Manufacturing News

> CorePharma gets closeout letter for NJ plant. Report

> WSJ: Novartis looks to unload CMO LTS Lohmann. Article

> FDA close to resolving all cancer drug shortages. Story

> Explosion, fire at Teva plant kills one, injures 30. More

And Finally... Long-term cancer survivors need special treatment and often aren't getting it. Report

Suggested Articles

Cannes Lions Health kicks off Monday, and attendees are looking for some breakouts—leading-edge tech, creativity and inspiration, for instance.

Bluebird has priced gene therapy Zynteglo at €1.575 million in Europe and promised a U.S. price in “reasonably close” range.

Generic pain drug maker Lannett is closing its plant in Wyoming and laying off the remaining 80 employees.